Intranasal fentanyl for the treatment of breakthrough pain in cancer patients. A randomised, double-blind, placebo-controlled, cross-over confirmatory trial testing fentanyl and placebo in eight breakthrough pain episodes.
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2013
At a glance
- Drugs Fentanyl (Primary)
- Indications Cancer pain
- Focus Adverse reactions; Therapeutic Use
- 08 Nov 2012 Planned number of patients changed from 150 to 175 as reported by EudraCT.
- 04 May 2012 Company added in the association field and additional lead trial centre identified as reported by ClinicalTrials.gov.
- 17 Aug 2008 Secondary endpoint 'Additional treatment required rescue medication' has not been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History